Your browser doesn't support javascript.
loading
Enhanced cardiac Akt/protein kinase B signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-targeted nuclear genes.
Wende, Adam R; O'Neill, Brian T; Bugger, Heiko; Riehle, Christian; Tuinei, Joseph; Buchanan, Jonathan; Tsushima, Kensuke; Wang, Li; Caro, Pilar; Guo, Aili; Sloan, Crystal; Kim, Bum Jun; Wang, Xiaohui; Pereira, Renata O; McCrory, Mark A; Nye, Brenna G; Benavides, Gloria A; Darley-Usmar, Victor M; Shioi, Tetsuo; Weimer, Bart C; Abel, E Dale.
Afiliación
  • Wende AR; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA Department of Pathology, Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • O'Neill BT; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA Department of Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Bugger H; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA Heart Center, Cardiology and Angiology I, Freiburg University, Freiburg, Germany.
  • Riehle C; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Roy J. and Lucille A. Carver College of Medicine,
  • Tuinei J; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA.
  • Buchanan J; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA.
  • Tsushima K; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Roy J. and Lucille A. Carver College of Medicine,
  • Wang L; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA.
  • Caro P; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA.
  • Guo A; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA Diabetes Institute at Ohio University, Heritage College of Osteopathic Medicine/Specialty Medicine, Athens, Ohio, USA.
  • Sloan C; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA.
  • Kim BJ; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA.
  • Wang X; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA.
  • Pereira RO; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Roy J. and Lucille A. Carver College of Medicine,
  • McCrory MA; Department of Pathology, Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Nye BG; Department of Pathology, Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Benavides GA; Department of Pathology, Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Darley-Usmar VM; Department of Pathology, Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Shioi T; Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Weimer BC; Department of Population Health and Reproduction, University of California, Davis, School of Veterinary Medicine, Davis, California, USA.
  • Abel ED; Program in Molecular Medicine and Division of Endocrinology, Metabolism, and Diabetes, University of Utah, School of Medicine, Salt Lake City, Utah, USA Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Roy J. and Lucille A. Carver College of Medicine,
Mol Cell Biol ; 35(5): 831-46, 2015 Mar.
Article en En | MEDLINE | ID: mdl-25535334
ABSTRACT
Sustained Akt activation induces cardiac hypertrophy (LVH), which may lead to heart failure. This study tested the hypothesis that Akt activation contributes to mitochondrial dysfunction in pathological LVH. Akt activation induced LVH and progressive repression of mitochondrial fatty acid oxidation (FAO) pathways. Preventing LVH by inhibiting mTOR failed to prevent the decline in mitochondrial function, but glucose utilization was maintained. Akt activation represses expression of mitochondrial regulatory, FAO, and oxidative phosphorylation genes in vivo that correlate with the duration of Akt activation in part by reducing FOXO-mediated transcriptional activation of mitochondrion-targeted nuclear genes in concert with reduced signaling via peroxisome proliferator-activated receptor α (PPARα)/PGC-1α and other transcriptional regulators. In cultured myocytes, Akt activation disrupted mitochondrial bioenergetics, which could be partially reversed by maintaining nuclear FOXO but not by increasing PGC-1α. Thus, although short-term Akt activation may be cardioprotective during ischemia by reducing mitochondrial metabolism and increasing glycolysis, long-term Akt activation in the adult heart contributes to pathological LVH in part by reducing mitochondrial oxidative capacity.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Núcleo Celular / Cardiomegalia / Proteínas Proto-Oncogénicas c-akt / Mitocondrias Límite: Animals Idioma: En Revista: Mol Cell Biol Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Núcleo Celular / Cardiomegalia / Proteínas Proto-Oncogénicas c-akt / Mitocondrias Límite: Animals Idioma: En Revista: Mol Cell Biol Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos